AGC Biologics, Biomeva, CMC Biologics Combine

January 26, 2018

The companies will be integrated to form the newly-branded AGC Biologics, which will specialize in customized contract development and manufacturing organization services for the scale-up and cGMP manufacture of protein-based therapeutics.

Asahi Glass Company (AGC) Bioscience, a glass and chemical producer under AGC, Biomeva, a contract manufacturing organization (CMO), and CMC Biologics, a contract biologics manufacturer, will be integrated to form the newly-branded AGC Biologics, effective Jan. 8, 2018.

AGC Biologics will provide contract development and manufacturing organization services from its facilities in the following sites: Seattle, Washington and Berkeley, California; Copenhagen, Denmark; Heidelberg, Germany; Chiba, Japan; and Yokohama, Japan.

The integrated company will specialize in customized services for the scale-up and cGMP manufacture of protein-based therapeutics, and plans to continue its global presence with microbial and mammalian capabilities by fulfilling early phase through late-phase projects, both at small and large scale. The company employs more than 850 employees globally.

AGC acquired CMC Biologics in February 2017, and Biomeva was acquired by AGC in September 2016. This announcement follows the appointment of Dr. Gustavo Mahler as president and CEO of AGC Biologics. Mahler has more than 20 years of scientific and executive management experience, and became president and CEO of CMC Biologics in 2015.

Source: AGC Biologics